Stratos Wealth Partners’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Stratos Wealth Partners’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.45K	Hold	18,040	–	–	﹤0.01%	1617
2025 Q4	$7.58K	Sell	18,040 -11,500	-39%	-$6.1K	﹤0.01%	1584
2025 Q3	$19.9K	Hold	29,540	–	–	﹤0.01%	1543
2025 Q2	$16K	Buy	29,540 +10,000	+51%	+$5.94K	﹤0.01%	1413
2025 Q1	$12.8K	Hold	19,540	–	–	﹤0.01%	1354
2024 Q4	$19.9K	Buy	19,540 +4,000	+26%	+$7.31K	﹤0.01%	1442
2024 Q3	$13.5K	Buy	+15,540	New	+$11.4K	﹤0.01%	1430
2020 Q4	–	Sell	-12,111	Closed	-$114K	–	1112
2020 Q3	$114K	Sell	12,111 -465	-4%	-$5.03K	﹤0.01%	963
2020 Q2	$113K	Buy	12,576 +685	+6%	+$6.36K	﹤0.01%	946
2020 Q1	$76K	Sell	11,891 -376	-3%	-$2.79K	﹤0.01%	884
2019 Q4	$103K	Sell	12,267 -100	-0.8%	-$920	﹤0.01%	950
2019 Q3	$112K	Buy	+12,367	New	+$139K	﹤0.01%	922
2018 Q4	–	Sell	-3,754	Closed	-$64K	–	2215
2018 Q3	$64K	Buy	+3,754	New	+$57.1K	﹤0.01%	1347
2018 Q2	–	Sell	-2,909	Closed	-$55K	–	2296
2018 Q1	$55K	Sell	2,909 -5	-0.2%	-$107	﹤0.01%	1527
2017 Q4	$48K	Buy	+2,914	New	+$43.4K	﹤0.01%	1533

Other funds holding SGMO

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Stratos Wealth Partners's SGMO Position: Q1 2026 in Review

Stratos Wealth Partners held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q1 2026 at 18,040 shares worth $4.45K. The position accounts for ﹤0.01% of the portfolio, ranked #1617.

Stratos Wealth Partners first reported a position in SGMO in Q4 2017 and has held it in 15 quarters since. The position peaked at $114K in Q3 2020. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

Stratos Wealth Partners held 18,040 shares of SANGAMO THERAPEUTICS INC worth $4.45K as of Q1 2026.
Stratos Wealth Partners left its SANGAMO THERAPEUTICS INC share count unchanged in Q1 2026.
SANGAMO THERAPEUTICS INC made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q1 2026, its #1617 holding.
Stratos Wealth Partners first reported a position in SANGAMO THERAPEUTICS INC in Q4 2017 and has held it in 15 quarters since.
Stratos Wealth Partners's SANGAMO THERAPEUTICS INC position peaked at $114K in Q3 2020.
112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.